Fangsheng Pharmaceutical: Increasing capital of Hong Kong joint venture subsidiary and promoting the transfer of pharmaceutical varieties.

Fangsheng Pharmaceutical announced that on January 28, 2026, its Hong Kong joint venture subsidiary Hong Kong Fangsheng Tang signed a supplementary agreement with related parties to increase its registered capital by HK$45 million. The company subscribed HK$27.05 million, increasing its shareholding from 50% to 57% after the capital injection. Apart from Hongjie Company, each party will make capital contributions in phases according to production and operation needs. Currently, Hong Kong Fangsheng Tang is upgrading the technology of 20 drug varieties it acquired in batches, and the transfer procedures of these acquired drugs are in preparation. This capital increase will not have a significant impact on the company's operations and drug license transfer transactions, but uncertainties exist in the mainland market registration and subsequent research evaluation, production, and sales of the drugs.